RxDoctor Payments Data

Brenda Crum

Family · Woodbridge, VANPI 1306883418

Payments from drug & device makers

$2,780in general payments, 2019–2025

Across 24 payments — averaging $115.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$800
  • AstraZeneca$334
  • Novo Nordisk$299
  • AbbVie$260
  • Neurocrine Biosciences, Inc.$242
  • Sandoz$141
  • plus $705 from 9 others

What the payments were for

  • Consulting fees$80029%
  • Food & beverage$1,94370%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,780 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$20,653
Medicare patients
96
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b13$124,603
GlatopaGlatiramer Acetate22$33,529
UbrelvyUbrogepant18$26,530
Carbamazepine ErCarbamazepine34$6,918
Pramipexole ErPramipexole Di-Hcl11$3,835
Carbidopa-Levodopa ErCarbidopa/Levodopa24$2,751
Oxcarbazepine22$2,218
Lisdexamfetamine Dimesylate11$1,547
Memantine Hcl76$1,530
Levetiracetam57$1,396
Gabapentin76$1,240
Divalproex Sodium ErDivalproex Sodium16$1,034
Primidone28$995
Donepezil Hcl103$970
Mirtazapine13$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SandozGlatopa$141$33,52922 claims
AbbVieUbrelvy$260$26,53018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Woodbridge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →